Asbestos & Mesothelioma Studies

Exposure to Asbestos With BAP1 Mutation Increases Risk of Mesothelioma

In a study presented today at the American Association for Cancer Research Annual Meeting 2024, researchers at Fox Chase Cancer Center showed that mice with a BAP1 germline mutation, after exposure to small levels of asbestos, had a greater chance of developing malignant mesothelioma. The study is being published in[…]

Read More »

Researchers Looked at Fibroblasts to Determine Their Role in Mesothelioma Growth

Malignant mesothelioma is a hard cancer to treat and is mainly caused by asbestos. It was widely used in construction, steel mills, and other industries. Mesothelioma is especially hard to treat because it grows and spreads quickly. There are unfortunately not many options for the treatment of mesothelioma. It takes[…]

Read More »

Targeting uPARAP Could Improve Mesothelioma Treatment

Mesothelioma is a hard cancer to treat that has low survival rates. This makes it a problem for doctors and researchers. A new study is looking to change this by looking at the collagen receptor uPARAP. The current clinical trial is looking at uPARAP, a protein that is found in[…]

Read More »

3D Printing and Optical Scanning Can Improve Mesothelioma Treatment

New treatments and technologies offer hope for mesothelioma patients. One technology, 3D printing and optical scanning, has the potential to help those suffering with mesothelioma. The technologies refine and enhance what is known as photodynamic therapy, a promising new approach for the management of mesothelioma. Photodynamic therapy is a unique[…]

Read More »

ADI-PEG20 Improves Survival in Mesothelioma Patients

ADI-PEG20 is showing promising results for mesothelioma. It is the first treatment to be fully incorporated with chemotherapy in 20 years. The drug will bring hope to thousands of mesothelioma survivors and their families. The drug works by blocking a cancer’s food supply, preventing the spread of the cancer. It[…]

Read More »

Galinpepimut-S Alongside Opdivo Improves Survival in Mesothelioma Patients

Sellas Life Sciences recently reported results from its Phase I clinical trial showing that survival was improved in pleural mesothelioma patients due to its treatment. The trial looked at the treatment called galinpepimut-S (GPS), an immunotherapy vaccine. There were 10 patients in the study with relapsed or refractory mesothelioma. Nine[…]

Read More »

Breath Test Could Improve Diagnosis of Mesothelioma

A new way to diagnose mesothelioma may have been discovered. Researchers have found that the exhaled breath of patients could have the potential to be a screening tool for malignant pleural mesothelioma. The information was presented at the International Association for the Study of Lung Cancer 2023 World Conference on[…]

Read More »

Occupational and Environmental Exposure to Asbestos Reduces Longevity in Patients

Mesothelioma is a hard cancer to treat that is mainly caused by asbestos. People with this cancer typically do not live very long after diagnosis, but some people live longer than expected. A study recently published in the journal Toxics looked at people with mesothelioma and asbestos-caused lung cancer. All[…]

Read More »

Altered CAR-T Cell Therapy for the Treatment of Mesothelioma

Immunotherapy is an innovative and groundbreaking way to treat cancer. It uses the immune system to fight and kill cancer cells. One immunotherapy treatment that is showing good results for certain cancers is called CAR-T cell therapy, which is able to target specific proteins on cancer cells. One of the[…]

Read More »

ADI-PEG 20 is Being Tested on Non-Epithelioid Mesothelioma

Polaris Group recently announced an application for a rolling submission of a new mesothelioma treatment. The Biologic License Application is the first step in becoming approved by the Food and Drug Administration. The treatment, known as ADI-PEG 20, is for the use on non-epithelioid mesothelioma patients alongside pemetrexed and platinum[…]

Read More »